Multi-Analyte Tumor Profiling for Refractory Solid Tumors
Understand the cancer from more than one angle. Exacta combines molecular profiling and laboratory drug-response information to support your oncologist’s review.
One service. Several layers of tumor information.
Exacta is a clinician-ordered laboratory profiling service from Datar Cancer Genetics. It examines molecular features of a solid tumor and, where suitable cells are available, their response to drugs in the laboratory.
The findings are brought together in a report for the oncology team. The purpose is to support a more informed review of the patient’s options, particularly when earlier treatments have failed.
Several layers of information.
Molecular findings + functional testing + clinical context
Findings, supporting evidence, candidate options, and limitations.
Why look beyond a single result?
Understand the molecular picture
DNA, RNA, and protein analyses contribute different information about the tumor.
Add functional observations
Laboratory testing examines how sampled living cells respond to tested drugs.
Connect findings to the patient
Clinical history and available evidence guide interpretation by the treating team.
How can this help patients?
When a cancer progresses, patients and clinicians often need to revisit the next step. Additional profiling may provide findings to discuss alongside existing results, standard treatments, and clinical trials. The report can help focus that conversation on the individual tumor.
Testing may also find no actionable option. A laboratory result cannot guarantee that a treatment will work or be safe for a particular person.
For patients & caregivers
Understand the service, prepare questions, and follow the path from testing to a discussion with your doctor.
For healthcare professionals
Review the product, clinical evidence, report contents, and ordering requirements.
Explore Exacta
The technology
DNA, RNA, proteins, viable-cell drug response, and integrated interpretation.
The process
A clear journey from the initial consultation through specimen analysis and report review.
The role of Exacta-AI
How decision support fits into the service and where human judgment remains essential.
News & research updates
Product milestones and publications, linked to their original sources.
Evidence you can examine
Explore the published studies behind the profiling approach, including RESILIENT and LIQUID IMPACT. Each summary identifies the design, patient population, reported outcomes, limitations, and funding disclosures.
Explore clinical evidence